Anticoagulants to prevent recurrent non-cardioembolic stroke
- PMID: 38101895
- DOI: 10.1016/S1474-4422(23)00464-7
Anticoagulants to prevent recurrent non-cardioembolic stroke
Conflict of interest statement
I report a previous contract from Bayer (PACIFIC-Stroke trial national leader);grants from Cerenovus (ENDOLOW trial) and the US National Institutes of Health (NIH); royalties or licenses from UpToDate; consulting fees from Basking Biosciences, Lumosa, and Shionogi; being the NIH-appointed Drug Safety Monitoring Board Chair of the Nourish Trial; and have received drugs and drug assays for the NIH-funded SISTER trial from Translational Sciences.
Comment on
-
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.Lancet Neurol. 2024 Jan;23(1):46-59. doi: 10.1016/S1474-4422(23)00403-9. Lancet Neurol. 2024. PMID: 38101902 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical